Clinical Trial Update: A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Surovatamig (AZD0486) in combination with Rituximab for previously untreated follicular lymphoma; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituximab (rituximab)
• Surovatamig

Snippet

Sponsor: AstraZeneca | Conditions: Untreated Follicular Lymphoma | Phase 3 | Status: RECRUITING